Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrics 2021 Apr 23

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Pediatrics 2021 Apr 23

DOI: 10.23736/S2724-5276.21.06327-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

SARS-CoV-2 associated multisystem inflammatory syndrome in children (MIS-C). A single center’s experience

Sevliya ÖCAL DEMİR 1 , Öykü TOSUN 2, Kübra ÖZTÜRK 3, Muhterem DUYU 4, Abdülmelik BUCAK 5, Gökhan AKKUŞ 5, Ali C. BAYRAKTAR 5, Hande N. DEMİREL 5, Sertaç ARSLANOĞLU 6, Fahri OVALI 6

1 Pediatric Infectious Diseases, Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey; 2 Pediatric Cardiology, Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey; 3 Pediatric Rheumatology, Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey; 4 Pediatric Intensive Care, Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey; 5 Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey; 6 Neonatology, Pediatric Department, SB Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital, Istanbul, Turkey


PDF


BACKGROUND: SARS-CoV-2 related multisystem inflammatory syndrome in children (MIS-C) is a newly defined clinical entity in pediatric ages resembles Kawasaki Disease or toxic shock syndrome. Here we aimed to raise awareness about this SARS-CoV-2 related syndrome.
METHODS: Children diagnosed with MIS-C and followed in Pediatric Clinic between November 2020 and January 2021, were included in study. Data about patients’ demographic characteristics, clinical and laboratory findings, treatment and outcomes were collected from medical records.
RESULTS: The median age of 20 children with MIS-C was 80.5 months, 11 of them were male. The most common symptoms at admission were fever (100%), abdominal pain (70%), myalgia (50%), and rash (50%). Lymphopenia, elevated inflammatory markers and cardiac enzymes were their main laboratory findings. Cardiac involvement (90%) consisted of myopericarditis, valvulitis, left ventricular dysfunction, and coronary arteritis. Symptoms mimicking acute appendicitis and ileus were due to gastrointestinal involvement (50%). Macular rash on the trunk, erythema on upper eyelids were striking. Empiric antibiotics and intravenous immunoglobulin were used in all patients, glucocorticoids (90%), anti-thrombotic (65%) and vasoactive (45%) agents were used according to severity of disease. Response to IVIG treatment was poor, whereas glucocorticoids have dramatic affect. Seven patients (35%) were monitored in intensive care unit, none of them required intubation, mechanic ventilation or ECMO. The median recovery time, that is, the period when fever subside and inflammatory markers returned to normal was 9.5 days.
CONCLUSIONS: Glucocorticoids has critical role in treatment of MIS-C, early recognition and treatment may decrease need for intensive care by providing rapid recovery.


KEY WORDS: SARS-CoV-2; Pediatric; MIS-C; PMIS; Hyperinflammatory syndrome

top of page